{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-24-000253","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.575733+00:00","generated_at":"2026-06-06T00:48:34.298551+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alnylam Q4 net product rev $346M, FY $1.24B (+39%); FY24 guide $1.4-1.5B; HELIOS-B readout late June/early July","bullets":["Q4 net product revenue $346M: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.","Full year 2023 net product revenue $1.24B, up 39% YoY; GAAP net loss per share ($3.52); non-GAAP ($1.61).","FY24 guidance: combined net product revenue $1.4B-$1.5B, plus collaboration and royalty revenue; operating expense guidance provided.","HELIOS-B Phase 3 top-line results expected late June or early July; updated statistical analysis plan announced.","FDA cleared Part B of ALN-APP Phase 1 study at doses up to 180 mg every six months; partial clinical hold remains for higher doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-24-000253","json":"https://secwatch.observer/filing/0001157523-24-000253.json","markdown":"https://secwatch.observer/filing/0001157523-24-000253.md","text":"https://secwatch.observer/filing/0001157523-24-000253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/0001157523-24-000253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/a53896787.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:48:34.298551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"892b2c60d3c61e04b2982d344e73a5eea6117cc0","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue $346 Million and $1,241 Million, Respectively.","evidence_excerpt":"Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/0001157523-24-000253-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$346 Million and $1,241 Million, Respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}